Survival and Recurrence With GLP-1 Receptor Agonists in Breast CancerSurvival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer
This cohort study of more than 800 000 patients with breast cancer evaluates the association between glucagon-like peptide-1 receptor agonist use and 10-year mortality and recurrence-free survival. This cohort study of more than 800 000 patients with breast cancer evaluates the association between glucagon-like peptide-1 receptor agonist use and 10-year mortality and recurrence-free survival.
Pooled analysis reveals semaglutide shows good efficacy in older adults aged over 65 yearsPooled analysis reveals semaglutide shows good efficacy in older adults aged over 65 years
A new analysis of the STEP trials carried out by semaglutide manufacturer Novo Nordisk has analyzed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations. The study is by Prof Luca Busetto from Read More
Could the ‘Ozempic Era’ shift blame for obesity from individuals to the food industry?Could the ‘Ozempic Era’ shift blame for obesity from individuals to the food industry?
An essay presented at the European Congress on Obesity in Istanbul, Turkey (12–15 May) suggests that a new age of obesity drugs could shift the blame for living with obesity from individuals to the food industry—just as smoking has been blamed on the tobacco industry and, to a lesser extent, alcohol consumption on the alcohol Read More
Study shows benefits in obesity-linked conditions of losing more weight with GLP-1 treatmentStudy shows benefits in obesity-linked conditions of losing more weight with GLP-1 treatment
New research presented at the European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12–15 May) shows that, following treatment for obesity or diabetes or both, using incretin-based drugs, losing more weight versus less weight, and losing a little weight versus gaining weight, both lead to a relatively lower risk of obesity-related conditions. The study is Read More
Study shows benefits in obesity-linked conditions of losing more weight with GLP-1 treatmentStudy shows benefits in obesity-linked conditions of losing more weight with GLP-1 treatment
New research presented at the European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12–15 May) shows that, following treatment for obesity or diabetes or both, using incretin-based drugs, losing more weight versus less weight, and losing a little weight versus gaining weight, both lead to a relatively lower risk of obesity-related conditions. The study is Read More
Technology receives FDA approval for breast cancer treatmentTechnology receives FDA approval for breast cancer treatment
More than a decade ago, Yale chemist Craig Crews founded a biotechnology company in New Haven based on his pioneering research into PROTACs (or PROteolysis TArgeting Chimera), a technology that treats certain types of cancer and other diseases by degrading the proteins that cause them.
Teens With T1D, Obesity Reaped Benefits of GLP-1s, Case Studies SuggestTeens With T1D, Obesity Reaped Benefits of GLP-1s, Case Studies Suggest
(MedPage Today) — Two insulin-dependent adolescents with type 1 diabetes and obesity had metabolic improvements after starting a low-dose GLP-1 agent, a case series showed. One year after adding injectable semaglutide (Ozempic, Wegovy) to lifestyle… (MedPage Today) — Two insulin-dependent adolescents with type 1 diabetes and obesity had metabolic improvements after starting a low-dose Read More
Gut microbiota play a role in metabolic health after bariatric surgery, finds studyGut microbiota play a role in metabolic health after bariatric surgery, finds study
Changes in gut microbiota after bariatric surgery are strongly linked to altered metabolic health and sustained improvement in type 2 diabetes, according to a study led by researchers at the University of Gothenburg.
Scientists discover why Ozempic works better for some peopleScientists discover why Ozempic works better for some people
Some people taking Ozempic-like diabetes drugs may be getting dramatically better results for a surprising reason: why they overeat in the first place. A year-long study in Japan found that people who tend to eat because tempting food looks or smells irresistible were much more likely to lose weight and improve blood sugar levels on Read More
Common inflammatory genes link pancreatic cancer with obesity and diabetesCommon inflammatory genes link pancreatic cancer with obesity and diabetes
New research shows that the same genes are active in pancreatic cancer, obesity and diabetes, helping to explain why people with metabolic disease often face poorer cancer outcomes and pointing to future ways to predict recurrence and develop more targeted treatments.